Galectin 3 complements BNP in risk stratification in acute heart failure

Gregory J. Fermann, Christopher J. Lindsell, Alan B. Storrow, Kimberly Hart, Matthew Sperling, Susan Roll, Neal L. Weintraub, Karen F. Miller, David J. Maron, Allen J. Naftilan, John A. McPherson, Douglas B. Sawyer, Robert Christenson, Sean P. Collins

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

Original languageEnglish (US)
Pages (from-to)706-713
Number of pages8
JournalBiomarkers
Volume17
Issue number8
DOIs
StatePublished - Dec 1 2012

Fingerprint

Galectin 3
Heart Failure
Brain Natriuretic Peptide
Kidney
Acute Kidney Injury
Multicenter Studies
Decision Making
Fibrosis
Heart Rate
Decision making

Keywords

  • Acute heart failure
  • Renal disease
  • Risk stratification

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

Fermann, G. J., Lindsell, C. J., Storrow, A. B., Hart, K., Sperling, M., Roll, S., ... Collins, S. P. (2012). Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers, 17(8), 706-713. https://doi.org/10.3109/1354750X.2012.719037

Galectin 3 complements BNP in risk stratification in acute heart failure. / Fermann, Gregory J.; Lindsell, Christopher J.; Storrow, Alan B.; Hart, Kimberly; Sperling, Matthew; Roll, Susan; Weintraub, Neal L.; Miller, Karen F.; Maron, David J.; Naftilan, Allen J.; McPherson, John A.; Sawyer, Douglas B.; Christenson, Robert; Collins, Sean P.

In: Biomarkers, Vol. 17, No. 8, 01.12.2012, p. 706-713.

Research output: Contribution to journalArticle

Fermann, GJ, Lindsell, CJ, Storrow, AB, Hart, K, Sperling, M, Roll, S, Weintraub, NL, Miller, KF, Maron, DJ, Naftilan, AJ, McPherson, JA, Sawyer, DB, Christenson, R & Collins, SP 2012, 'Galectin 3 complements BNP in risk stratification in acute heart failure', Biomarkers, vol. 17, no. 8, pp. 706-713. https://doi.org/10.3109/1354750X.2012.719037
Fermann GJ, Lindsell CJ, Storrow AB, Hart K, Sperling M, Roll S et al. Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers. 2012 Dec 1;17(8):706-713. https://doi.org/10.3109/1354750X.2012.719037
Fermann, Gregory J. ; Lindsell, Christopher J. ; Storrow, Alan B. ; Hart, Kimberly ; Sperling, Matthew ; Roll, Susan ; Weintraub, Neal L. ; Miller, Karen F. ; Maron, David J. ; Naftilan, Allen J. ; McPherson, John A. ; Sawyer, Douglas B. ; Christenson, Robert ; Collins, Sean P. / Galectin 3 complements BNP in risk stratification in acute heart failure. In: Biomarkers. 2012 ; Vol. 17, No. 8. pp. 706-713.
@article{3f9c8c6629da43f9849a4f89ba233a98,
title = "Galectin 3 complements BNP in risk stratification in acute heart failure",
abstract = "Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.",
keywords = "Acute heart failure, Renal disease, Risk stratification",
author = "Fermann, {Gregory J.} and Lindsell, {Christopher J.} and Storrow, {Alan B.} and Kimberly Hart and Matthew Sperling and Susan Roll and Weintraub, {Neal L.} and Miller, {Karen F.} and Maron, {David J.} and Naftilan, {Allen J.} and McPherson, {John A.} and Sawyer, {Douglas B.} and Robert Christenson and Collins, {Sean P.}",
year = "2012",
month = "12",
day = "1",
doi = "10.3109/1354750X.2012.719037",
language = "English (US)",
volume = "17",
pages = "706--713",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Galectin 3 complements BNP in risk stratification in acute heart failure

AU - Fermann, Gregory J.

AU - Lindsell, Christopher J.

AU - Storrow, Alan B.

AU - Hart, Kimberly

AU - Sperling, Matthew

AU - Roll, Susan

AU - Weintraub, Neal L.

AU - Miller, Karen F.

AU - Maron, David J.

AU - Naftilan, Allen J.

AU - McPherson, John A.

AU - Sawyer, Douglas B.

AU - Christenson, Robert

AU - Collins, Sean P.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

AB - Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

KW - Acute heart failure

KW - Renal disease

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=84870482586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870482586&partnerID=8YFLogxK

U2 - 10.3109/1354750X.2012.719037

DO - 10.3109/1354750X.2012.719037

M3 - Article

C2 - 22998064

AN - SCOPUS:84870482586

VL - 17

SP - 706

EP - 713

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 8

ER -